Curovir is developing a novel antiviral, CUR-N399, for treatment of infections caused by enteroviruses (EV).
EV has been identified as one of the most common infections in mankind and is estimated to cause more than one billion infections globally each year. Poliovirus probably the most well-known EV, caused around half a million cases of paralysis or death each year during its peak in the mid-20th century before the first polio vaccine was launched. EV is also one of the main viruses causing the common cold. In addition, data shows that CUR-N399 is also effective against respiratory syncytial virus (RSV). Although most EV and RSV infections are mild or even asymptomatic, they can also be serious or even life-threatening especially in vulnerable groups of people such as young children, elderly and immune compromised patients. Currently, there are no antiviral treatments approved for treating these infections.
CUR-N399 is primarily developed for treatment of exacerbations in chronic obstructive pulmonary disease (COPD) and asthma but may also be an important treating serious cases of EV and RSV infection as well as to increase the preparedness for a possible medically important EV epidemic/pandemic.
